Department of Medicinal Chemistry, Roche Palo Alto, Palo Alto, CA 94304, USA.
Bioorg Med Chem Lett. 2010 Mar 1;20(5):1693-6. doi: 10.1016/j.bmcl.2010.01.038. Epub 2010 Jan 25.
Here we report on the discovery of a series of maleimides which have high potency and good selectivity for GSK-3beta. The incorporation of polar groups afforded compounds with good bioavailability. The most potent compound 34 has an IC(50) of 0.6nM for GSK-3beta, over 100-fold selectivity against a panel of other kinases, and shows efficacy in rat osteoporosis models. The X-ray structure of GSK-3beta protein with 34 bound revealed the binding mode of the template and provided insights for future optimization opportunities.
在这里,我们报告了一系列马来酰亚胺的发现,它们对 GSK-3β 具有高活性和良好的选择性。极性基团的引入赋予了具有良好生物利用度的化合物。最有效的化合物 34 对 GSK-3β 的 IC50 为 0.6nM,对一组其他激酶具有超过 100 倍的选择性,并且在大鼠骨质疏松模型中显示出疗效。与 34 结合的 GSK-3β 蛋白的 X 射线结构揭示了模板的结合模式,并为未来的优化机会提供了见解。